Millennium Management’s Longboard Pharmaceuticals LBPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-55,644
Closed -$1.85M – 6689
2024
Q3
$1.85M Sell
55,644
-114,199
-67% -$3.93M ﹤0.01% 3768
2024
Q2
$4.59M Sell
169,843
-363,192
-68% -$7.16M ﹤0.01% 2805
2024
Q1
$11.5M Buy
+533,035
New +$11.6M ﹤0.01% 2048
2023
Q4
– Sell
-17,153
Closed -$95.4K – 6878
2023
Q3
$95.4K Buy
+17,153
New +$110K ﹤0.01% 5355
2023
Q2
– Sell
-1,047,705
Closed -$4.12M – 7149
2023
Q1
$4.12M Buy
1,047,705
+59,993
+6% +$293K ﹤0.01% 2779
2022
Q4
$3.12M Sell
987,712
-66,847
-6% -$268K ﹤0.01% 3189
2022
Q3
$3.92M Buy
1,054,559
+11,343
+1% +$41.9K ﹤0.01% 3141
2022
Q2
$3.22M Sell
1,043,216
-2,713
-0.3% -$12.5K ﹤0.01% 3224
2022
Q1
$5.43M Buy
1,045,929
+820,372
+364% +$3.89M ﹤0.01% 2839
2021
Q4
$1.09M Buy
+225,557
New +$1.53M ﹤0.01% 4332
2021
Q3
– Sell
-54,443
Closed -$497K – 7672
2021
Q2
$497K Sell
54,443
-135,906
-71% -$1.35M ﹤0.01% 5317
2021
Q1
$3.11M Buy
+190,349
New +$3.11M ﹤0.01% 3106

Millennium Management's LBPH Position: Q4 2024 in Review

Millennium Management sold out of Longboard Pharmaceuticals (LBPH) in Q4 2024, closing a stake of 55,644 shares — an estimated $1.85M sold.

Millennium Management first reported a position in LBPH in Q1 2021 and held it in 12 quarters. The position peaked at $11.5M in Q1 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

  • Millennium Management reported no remaining Longboard Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Millennium Management sold 55,644 Longboard Pharmaceuticals shares in Q4 2024, an estimated $1.85M.
  • Millennium Management first reported a position in Longboard Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Millennium Management's Longboard Pharmaceuticals position peaked at $11.5M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.